马德里方案:经会阴多参数磁共振融合与微超声引导前列腺活检
本研究评估了经会阴前列腺活检中联合使用多参数磁共振/超声融合靶向活检与微超声靶向活检的前列腺癌检出准确性。194例连续患者在同一手术中接受两种靶向活检,结果显示联合微超声和磁共振可显著提高临床显著前列腺癌的检出率(p<0.001),且无感染并发症。
要点
- 联合微超声和磁共振融合靶向活检可显著提高临床显著前列腺癌检出率。
- 微超声额外发现11%的前列腺癌,其中92%为临床显著癌。
- PI-RADS和PRI-MUS是临床显著前列腺癌的强预测因子(AUC 0.76)。
核心结论
- 经会阴微超声引导活检联合多参数磁共振融合活检对前列腺癌和临床显著前列腺癌诊断准确性高,且无感染并发症。
研究设计与样本
- 前瞻性单中心研究,纳入194例连续患者,于2018年2月至2019年9月在同一手术中接受经会阴实时靶向微超声(ExactVu™)和超声融合靶向活检(BiopSee®)。
- 活检使用附着于29 MHz高分辨率微超声换能器的经会阴针导引器进行。
主要发现
- 前列腺癌总体阳性率为56%(108例),临床显著前列腺癌(Gleason分级组>1)阳性率为42%(81例)。
- 联合微超声和磁共振检测到的临床显著前列腺癌显著多于系统活检(p<0.001)。
- 微超声发现12例(11%)其他技术均未检出的前列腺癌,其中11例(92%)为临床显著前列腺癌。
- PI-RADS和PRI-MUS在逻辑回归模型中是临床显著前列腺癌的强预测因子(AUC 0.76)。
- 无发热或临床感染发生,17例(8.7%)出现轻微并发症(Clavien Dindo I级)。
关键数值与推荐
- 对于PSA>4 ng/ml且PI-RADS>3的患者,PRI-MUS 4与PRI-MUS 5之间的检出率有所提高(Gleason分级组>1的检出率从52%升至92%)。
临床怎么用
- 经会阴途径联合微超声和磁共振融合靶向活检可用于前列腺癌诊断,尤其有助于检出临床显著前列腺癌,且感染风险低。
- PRI-MUS评分可与PI-RADS结合用于风险分层。
局限性
- 本研究为单中心、非随机设计,样本量有限,结果需在大型随机临床试验中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We assessed the prostate cancer detection accuracy of transperineal prostate biopsy using multiparametric magnetic resonance imaging/ultrasound fusion targeted biopsy and micro-ultrasound during the same procedure. Micro-ultrasound is a new high-resolution imaging system that allows real-time targeted biopsy. MATERIALS AND METHODS: A total of 194 consecutive patients underwent transperineal prostate biopsies using real-time targeted micro-ultrasound (ExactVu™) and ultrasound fusion targeted biopsy (BiopSee®) in the same procedure, from February 2018 to September 2019. Biopsies were performed using a transperineal needle guide attached to the 29 MHz high-resolution micro-ultrasound transducer. RESULTS: The overall positive rate was 56% (108) for prostate cancer and 42% (81) for clinically significant prostate cancer (Gleason Grade Group greater than 1), and adding micro-ultrasound and magnetic resonance imaging detected significantly more clinically significant prostate cancer than systematic biopsy (p <0.001). Micro-ultrasound found 12 of 108 (11%) prostate cancers that were missed by all other techniques and 11 (92%) were clinically significant prostate cancer. PI-RADS® and PRI-MUS™ (Prostate Risk Identification Using Micro-Ultrasound) were strong predictors of clinically significant prostate cancer in a logistic regression model (AUC 0.76). For prostate specific antigen greater than 4 ng/ml, PI-RADS greater than 3, there was an improvement in detection rate between PRI-MUS 4 and PRI-MUS 5 (52% Gleason Grade Group greater than 1 to 92% Gleason Grade Group greater than 1). No fever or clinical infection was observed and 17 (8.7%) patients presented with minor complications (Clavien Dindo I). CONCLUSIONS: This is the first study using a transperineal approach for micro-ultrasound guided biopsy and multiparametric magnetic resonance imaging fusion biopsy. The results show a high accuracy for prostate cancer and clinically significant prostate cancer diagnosis, without infectious complications. The proposed method should be validated in large randomized clinical trials.
引用
- Rodríguez Socarrás ME, Gomez Rivas J, Cuadros Rivera V, et al. Prostate Mapping for Cancer Diagnosis: The Madrid Protocol. Transperineal Prostate Biopsies Using Multiparametric Magnetic Resonance Imaging Fusion and Micro-Ultrasound Guided Biopsies. J Urol. 2020. PMID: 32314932. doi:10.1097/JU.0000000000001083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。